Welcome to our dedicated page for Novabay Pharma news (Ticker: NBY), a resource for investors and traders seeking the latest updates and insights on Novabay Pharma stock.
NovaBay Pharmaceuticals (NBY) delivers innovative non-antibiotic anti-infectives for ophthalmic care, wound management, and dermatological conditions. This page provides investors and healthcare professionals with timely updates on the company’s scientific advancements, regulatory milestones, and market strategies.
Access consolidated news about NBY’s Neutrox™ product line, including Avenova for chronic eye conditions, and developments in its Aganocide® compound research. Stay informed about financial disclosures, partnership announcements, and clinical trial outcomes through verified press releases and analysis.
Key updates include FDA submissions, international distribution expansions, and peer-reviewed study results. Our repository ensures efficient tracking of NovaBay’s progress in addressing antibiotic resistance challenges through its patented antimicrobial technologies.
Bookmark this page for direct access to NBY’s latest corporate communications. Check regularly for insights into commercialization efforts and research breakthroughs shaping the future of non-antibiotic therapies.
NovaBay Pharmaceuticals (NBY) reported a net product revenue of $2.1 million for Q2 2021, down from $4.0 million in Q2 2020, impacted by the absence of KN95 mask sales. However, Avenova revenue surged 65% year-over-year to $1.9 million. Gross margin improved to 71% from 49% due to higher Avenova sales. Operating expenses rose to $3.4 million from $3.0 million, driven by increased digital marketing costs. The net loss narrowed to $1.9 million ($0.04 per share) compared to $4.5 million ($0.15 per share) in Q2 2020. Cash reserves stood at $10.3 million as of June 30, 2021.
NovaBay Pharmaceuticals (NYSE American: NBY) will report its financial results for the three and six months ending June 30, 2021, after market close on August 12, 2021. The company will host a conference call for the investment community at 4:30 p.m. ET the same day. Participants can pre-register for the call to obtain a passcode and unique PIN for immediate access. The live webcast will also be available, with a replay accessible until September 2, 2021. NovaBay focuses on anti-infective consumer products, including the clinically proven Avenova spray.
NovaBay Pharmaceuticals (NYSE American: NBY) has partnered with ImprimisRx, a subsidiary of Harrow Health (Nasdaq: HROW), for the promotion of its product Avenova, a 0.01% hypochlorous acid solution for eye care. This collaboration aims to enhance national sales, marketing, and distribution efforts for Avenova, which addresses chronic eye conditions affecting 30 million Americans. The partnership is expected to improve accessibility to prescription Avenova through a streamlined pharmaceutical model.
NovaBay Pharmaceuticals (NYSE American: NBY) announced its participation in upcoming investment conferences, including the Ladenburg Thalmann Virtual Healthcare Conference on July 14, where management will present at 4:30 p.m. Eastern. The company reported record Avenova unit sales for three consecutive quarters and is targeting a dry eye market of 16 million Americans. NovaBay is also exploring growth opportunities through acquisitions in ophthalmic and skincare products to enhance shareholder value.
NovaBay Pharmaceuticals (NYSE American: NBY) has launched the i-Chek Illuminated Eye Examination Mirror, designed for at-home eye care. This lightweight, handheld mirror provides 10x magnification, allowing users to assess their eyelids and lashes and visualize the effects of their Avenova antimicrobial spray. The i-Chek complements Avenova and aims to enhance customer experience in managing bacterial dry eye. Priced at $29.99, it is available on Amazon and Avenova.com. The company plans to introduce a lubricating dry eye drop later this year to expand its product offerings.
NovaBay Pharmaceuticals (NBY) reported Q1 2021 financial results, highlighting a milestone in OTC revenue with Avenova exceeding $1 million for the first time. The OTC channel now represents 79% of Avenova revenue, up from 51% year-over-year. First-quarter net product revenue was $1.8 million, with Avenova revenue up to $1.6 million from $1.5 million in 2020. Gross margin improved to 75% from 69%. The company continues to expand product offerings and digital advertising strategies, maintaining a net loss of $1.5 million, or $0.04 per share. Cash reserves stood at $10.5 million as of March 31, 2021.
NovaBay Pharmaceuticals (NYSE American: NBY) will release its financial results for Q1 2021 on May 6, 2021, after market close. An investment community conference call is scheduled for the same day at 4:30 p.m. ET. Participants can pre-register online to gain immediate access, or dial in for live access. A replay will be available post-call until May 27, 2021. NovaBay is known for its innovative anti-infective consumer products, including Avenova, CelleRx, and NeutroPhase, utilizing a patented pharmaceutical-grade hypochlorous acid.
NovaBay Pharmaceuticals (NYSE American: NBY) has launched its new Avenova Warm Eye Compress to aid in alleviating symptoms related to blepharitis, dry eye disease, and other eye conditions. This reusable compress complements the company’s existing Avenova lid and lash spray and aims to hydrate and lubricate the eyes. It promotes meibomian gland function, enhancing tear production and preventing rapid tear evaporation. Users can easily heat the compress in a microwave and reuse it after cleaning.
NovaBay Pharmaceuticals reported strong financial results for 2020, with a 51% increase in net product revenue, totaling $9.9 million. Fourth quarter revenue reached $1.9 million, up 10% year-over-year. Avenova sales, key to growth, accounted for $1.5 million in Q4 2020. The company improved its balance sheet, reducing cash burn and eliminating major debts. Operating loss for 2020 was $6.4 million, a 32% decrease from 2019. Cash reserves increased to $12 million. Future plans include expanding sales and exploring acquisitions in skincare and ophthalmic products.
NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) will disclose its financial results for the year ending December 31, 2020, after market close on March 25, 2021. The company will host a conference call at 4:30 p.m. ET on the same day to discuss these results with investors. Participants can pre-register for the call to receive a unique PIN for immediate access, or join live by dialing designated phone numbers. A replay will be available until April 15, 2021. More details can be found on NovaBay's investor website.
